AUS
NZ
UK
CA
USA
IND
As the S&P/ASX 200 Index is gaining traction on Friday, soaring by 38.70 points or 0.50% to 7,760.30 and crossing above its 50-day moving average in afternoon trading. However, not all ASX shares are basking in the market's upward momentum. Here, we delve into two ASX-listed companies that are trailing behind, shedding light on the factors contributing to their decline.
De Grey Mining Limited (ASX: DEG)
De Grey Mining's share price is grappling with a 3% slump, settling at AU$1.234. The decline follows the conclusion of an institutional entitlement offer and placement by the gold developer. Through this initiative, De Grey Mining has successfully raised approximately AU$ 514.3 million, issuing new shares at a discounted rate of AU$1.10 each. These funds, coupled with existing capital, are earmarked to finance the equity component of the Hemi Gold Project in Western Australia. Glenn Jardine, the Managing Director, underscores the significance of shareholder support, affirming that it underscores the project's quality on a global scale.
Neuren Pharmaceuticals Ltd (ASX: NEU)
Neuren Pharmaceuticals is witnessing a nearly 2% drop in its share price, sliding to AU$19.00. The pharmaceutical company's decline comes in the wake of its quarterly sales update release on Thursday. The report revealed that its partner, Acadia Pharmaceuticals (NASDAQ:ACAD), recorded Daybue's net sales in the United States at US$75.9 million. Although slightly below guidance, Acadia reiterated its FY 2024 forecast for net sales, estimated between US$370 million and US$420 million. Despite this assurance, investors seem to be responding cautiously to the deviation from initial expectations.
In a market climate characterised by fluctuating sentiments and evolving dynamics, navigating through fluctuations in share prices can be a challenging endeavor. While some companies experience buoyancy propelled by positive developments, others contend with headwinds that dampen investor enthusiasm.
For De Grey Mining, the completion of its institutional entitlement offer and placement marks a significant milestone in its quest to advance the Hemi Gold Project. Despite the initial market reaction, the company remains optimistic about its prospects, buoyed by the robust support from both existing and new shareholders.
Similarly, Neuren Pharmaceuticals finds itself amidst market scrutiny following its quarterly sales update. Despite falling short of initial expectations, the company's partnership with Acadia Pharmaceuticals continues to hold promise, with reiterated guidance for FY 2024 instilling confidence in its long-term trajectory.
